Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 34, pp. 3844-3850
Open Access | Times Cited: 305

Showing 1-25 of 305 citing articles:

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, et al.
Leukemia (2018) Vol. 32, Iss. 5, pp. 1057-1069
Open Access | Times Cited: 491
Anemia of Inflammation
Tomas Ganz
New England Journal of Medicine (2019) Vol. 381, Iss. 12, pp. 1148-1157
Closed Access | Times Cited: 431
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, et al.
The Lancet Haematology (2017) Vol. 5, Iss. 2, pp. e73-e81
Closed Access | Times Cited: 264
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Ayalew Tefferi
American Journal of Hematology (2020) Vol. 96, Iss. 1, pp. 145-162
Open Access | Times Cited: 257
Targeting fibrosis: mechanisms and clinical trials
Manyu Zhao, Liqun Wang, Mengzhu Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 252
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 214
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 801-821
Open Access | Times Cited: 169
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz, Jean‐Jacques Kiladjian
Leukemia (2020) Vol. 35, Iss. 1, pp. 1-17
Open Access | Times Cited: 146
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, et al.
The Lancet (2023) Vol. 401, Iss. 10373, pp. 269-280
Closed Access | Times Cited: 116
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
The role of TBK1 in cancer pathogenesis and anticancer immunity
Austin P. Runde, Ryan Mack, Peter Breslin S.J., et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 79
Myelofibrosis
Francesco Passamonti, Barbara Mora
Blood (2022) Vol. 141, Iss. 16, pp. 1954-1970
Open Access | Times Cited: 70
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 32, pp. 4993-5004
Open Access | Times Cited: 56
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
William Vainchenker, Emilie Leroy, Laure Gilles, et al.
F1000Research (2018) Vol. 7, pp. 82-82
Open Access | Times Cited: 142
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Cancer (2019) Vol. 126, Iss. 6, pp. 1243-1252
Open Access | Times Cited: 127
Targeting the JAK/STAT pathway in solid tumors
Zoya Qureshy, Daniel E. Johnson, Jennifer R. Grandis
Journal of Cancer Metastasis and Treatment (2020) Vol. 2020
Open Access | Times Cited: 116
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, et al.
Blood Advances (2020) Vol. 4, Iss. 18, pp. 4282-4291
Open Access | Times Cited: 105
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Prithviraj Bose, Srđan Verstovšek
Blood (2017) Vol. 130, Iss. 2, pp. 115-125
Open Access | Times Cited: 99
Current and future status of JAK inhibitors
Donal P. McLornan, Janet Pope, Jason Gotlib, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 803-816
Closed Access | Times Cited: 89
Management of myelofibrosis after ruxolitinib failure
Claire Harrison, Nicolaas Schaap, Ruben A. Mesa
Annals of Hematology (2020) Vol. 99, Iss. 6, pp. 1177-1191
Open Access | Times Cited: 87
Ruxolitinib
Stefanie Ajayi, Heiko Becker, Heike Reinhardt, et al.
Recent results in cancer research/Recent Results in Cancer Research (2018), pp. 119-132
Closed Access | Times Cited: 85
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Katrin Pansy, Barbara Uhl, Jelena Krstić, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13311-13311
Open Access | Times Cited: 82
STAT3 signaling in ovarian cancer: a potential therapeutic target
Renba Liang, Xishan Chen, Li Chen, et al.
Journal of Cancer (2019) Vol. 11, Iss. 4, pp. 837-848
Open Access | Times Cited: 80
The mechanisms of pathological extramedullary hematopoiesis in diseases
Xinxin Yang, Degao Chen, Haixia Long, et al.
Cellular and Molecular Life Sciences (2020) Vol. 77, Iss. 14, pp. 2723-2738
Closed Access | Times Cited: 74
Fedratinib in myelofibrosis
Ann Mullally, John Hood, Claire Harrison, et al.
Blood Advances (2020) Vol. 4, Iss. 8, pp. 1792-1800
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top